Pyxis Oncology, Inc.
PYXS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001782223
In the last 90 days, Pyxis Oncology, Inc. insiders filed 0 open-market purchases and 1 sale; 76 institutions reported holding it in 13F filings for Q2 2026, worth $101.1M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Pyxis Oncology, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $107.1K in total
- Insiders trading
- 1
- Net value
- −$107.1K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Pyxis Oncology, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Civik Thomas | CEO & Chairman of the Board | 206,186 | Sep 8, 2026 | 3 |
| Dupont Jakob | Director | 38,741 | Aug 20, 2026 | 3 |
| Flavin John L | Director | 413,015 | Mar 25, 2026 | 1 |
| Lewis-Hall Freda C | Director | 241,405 | Mar 25, 2026 | 1 |
| Metzger Michael A | Director | – | Mar 25, 2026 | 1 |
| Humphrey Rachel | Director | 81,309 | Mar 25, 2026 | 2 |
| Cline Darren S | Director | 251,405 | Mar 25, 2026 | 1 |
| Wadhane Jitendra | Prin Fin & Acct Officer | 512,882 | Mar 25, 2026 | 1 |
| Palani Santhosh | Director | 6,000 | Mar 25, 2026 | 1 |
| Sullivan Lara | President ,CEO & CMO | 2,403,882 | Apr 2, 2025 | 0 |
| Yanchik Connealy Pamela | CFO & COO | 1,199,143Indirect | Apr 2, 2025 | 0 |
| Kobayashi Ken | Chief Medical Officer | – | Dec 29, 2023 | 0 |
| Feingold Jay | Chief Medical Officer | 730,345 | Mar 28, 2023 | 0 |
| Pfizer Inc | 10% Owner | 5,952,263 | Mar 23, 2023 | 0 |
| Pfizer Ventures (US) LLC | 10% Owner | 5,952,263 | Mar 23, 2023 | 0 |
| Barclays PLC | 10% Owner | – | Apr 27, 2022 | 0 |
| Chin Mark | Other: Former Director | 0Indirect | Apr 25, 2022 | 0 |
| Bayer Aktiengesellschaft | Other: Former 10% Owner | 2,742,338 | Oct 15, 2021 | 0 |
| Bayer World Investments B.V. | Other: Former 10% Owner | 2,742,338 | Oct 15, 2021 | 0 |
| Cormorant Asset Management, LP | Other: Former 10% Owner | 1,118,854Indirect | Oct 15, 2021 | 0 |
| Chen Bihua | Director, Other: Former 10% Owner | 1,118,854Indirect | Oct 15, 2021 | 0 |
| Cormorant Global Healthcare Master Fund, LP | Other: Former 10% Owner | 1,118,854Indirect | Oct 15, 2021 | 0 |
| Cormorant Private Healthcare Fund III LP | Other: Former 10% Owner | 1,118,854Indirect | Oct 15, 2021 | 0 |
| Shah Ritu | Chief Operating Officer | – | Oct 12, 2021 | 0 |
| Herbst Ronald | Chief Scientific Officer | – | Oct 12, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 2, 2026 (view filing)4:30 PM ET | Jun 30 | 2 days | Dupont JakobDirector | SSale | −35.0K | $3.06 | −$107.1K | −47.5%38.7K after | 10b5-1 |
| Mar 25, 2026 (view filing) | Apr 14-21, 2025 | 345 daysLate | Humphrey RachelDirector | SSale | −15.5K | $1.02 | −$15.9K | −16.0%81.3K after | 3 lots10b5-1 |
| Nov 27, 2024 (view filing) | Nov 26 | 1 day | Yanchik Connealy PamelaCFO & COO | PPurchase | +88.8K | $1.96 | +$174.4K | +8.0%1.20M after | 2 lots |
| Sep 28, 2023 (view filing) | Sep 28 | Same day | Yanchik Connealy PamelaCFO and COO | PPurchase | +8.00K | $1.87 | +$15.0K | +1.0%818.5K after | |
| Sep 27, 2023 (view filing) | Sep 27 | Same day | Wadhane JitendraChief Accounting Officer | PPurchase | +2.50K | $1.87 | +$4.67K | +1.1%226.9K after | |
| Sep 27, 2023 (view filing) | Sep 27 | Same day | Yanchik Connealy PamelaCFO and COO | PPurchase | +6.43K | $1.85 | +$11.9K | +0.8%810.5K after | |
| Sep 25, 2023 (view filing) | Sep 25 | Same day | Wadhane JitendraChief Accounting Officer | PPurchase | +5.00K | $1.77 | +$8.85K | +2.3%224.4K after | |
| Sep 25, 2023 (view filing) | Sep 25 | Same day | Yanchik Connealy PamelaCFO and COO | PPurchase | +12.0K | $1.67 | +$20.0K | +1.5%804.1K after | |
| Sep 22, 2023 (view filing) | Sep 22 | Same day | Wadhane JitendraChief Accounting Officer | PPurchase | +2.50K | $1.74 | +$4.35K | +1.2%219.4K after | |
| Sep 22, 2023 (view filing) | Sep 22 | Same day | Yanchik Connealy PamelaCFO and COO | PPurchase | +5.00K | $1.74 | +$8.70K | +0.6%792.1K after | |
| Sep 18, 2023 (view filing) | Sep 14-18 | 4 days | Sullivan LaraPresident and CEO | SSale | −8.64K | $2.10 | −$18.2K | −0.4%2.40M after | 2 lots |
| Sep 13, 2023 (view filing) | Sep 11-13 | 2 days | Sullivan LaraPresident and CEO | SSale | −27.9K | $2.27 | −$63.3K | −1.1%2.60M after | 3 lots |
| Mar 23, 2023 (view filing)4:14 PM ET | Mar 17 | 6 days | Pfizer Inc and 1 other10% Owner | PPurchaseCommon Stock, $0.001 par value per share | +1.81M | $2.76 | +$5.00M | +43.8%5.95M after | Amended |
| Apr 25, 2022 (view filing) | Apr 21 | 4 days | Chin MarkOther: Former Director | SSale | −1.75M | $3.05 | −$5.32M | −100.0%0 after | |
| Dec 9, 2021 (view filing) | Dec 8 | 1 day | Cline Darren SDirector | PPurchase | +10.0K | $9.39 | +$93.9K | New position10.0K after | |
| Nov 19, 2021 (view filing) | Nov 18 | 1 day | Civik ThomasDirector | PPurchase | +15.7K | $12.74 | +$200.0K | New position15.7K after | |
| Oct 15, 2021 (view filing)4:12 PM ET | Oct 13 | 2 days | Chen Bihua and 3 othersDirector, Other: Former 10% Owner | PPurchase | +450.0K | $16.00 | +$7.20M | +67.3%1.12M after | |
| Oct 15, 2021 (view filing) | Oct 13 | 2 days | Chin MarkDirector | PPurchase | +312.5K | $16.00 | +$5.00M | +21.8%1.75M after |